Heron Therapeutics (HRTX) Current Assets (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Current Assets came in at $229.0 million in Q1 2026, up 7.58% YoY from $212.8 million in Q1 2025, and down 3.81% on a QoQ basis from $238.1 million in Q4 2025.
Heron Therapeutics (HRTX) Current Assets (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Current Assets data on file, last reported at $229.0 million in Q1 2026.
- Quarterly Current Assets rose 7.58% year-over-year to $229.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229.0 million (up 7.58% YoY) and the FY2025 annual result came in at $238.1 million, up 13.9% from the prior year.
- Current Assets eased to $229.0 million in Q1 2026, from $238.1 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $238.1 million in Q4 2025 to a low of $165.3 million in Q2 2023.
- A 5-year average of $204.3 million and a median of $205.4 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets plunged 47.06% — and 2025, when it gained 17.53%.
- Tracing HRTX's Current Assets over 5 years: stood at $205.4 million in 2022, then dropped by 8.11% to $188.8 million in 2023, then advanced by 10.72% to $209.0 million in 2024, then grew by 13.9% to $238.1 million in 2025, then declined by 3.81% to $229.0 million in 2026.
- The last three Current Assets figures came in at $229.0 million (Q1 2026), $238.1 million (Q4 2025), and $229.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 229.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 229.85 Mn |
| Mar 31, 2026 | 228.98 Mn |
| Dec 31, 2025 | 238.07 Mn |
| Sep 30, 2025 | 229.40 Mn |
| Jun 30, 2025 | 210.92 Mn |
| Mar 31, 2025 | 212.84 Mn |
| Dec 31, 2024 | 209.01 Mn |
| Sep 30, 2024 | 195.19 Mn |
| Jun 30, 2024 | 191.17 Mn |
| Mar 31, 2024 | 185.90 Mn |
| Dec 31, 2023 | 188.77 Mn |
| Sep 30, 2023 | 193.98 Mn |
| Jun 30, 2023 | 165.28 Mn |
| Mar 31, 2023 | 178.16 Mn |
| Dec 31, 2022 | 205.44 Mn |
| Sep 30, 2022 | 223.80 Mn |
| Jun 30, 2022 | 194.21 Mn |
| Mar 31, 2022 | 222.59 Mn |
| Dec 31, 2021 | 254.42 Mn |
| Sep 30, 2021 | 315.05 Mn |